Determining the Impact of Roller Compaction Processing Conditions on Granulate and API Properties: Impact of Formulation API Load

Previous work demonstrated that roller compaction of a 40%w/w theophylline–loaded formulation resulted in granulate consisting of un-compacted fractions which were shown to constitute between 34 and 48%v/v of the granulate dependent on processing conditions. The active pharmaceutical ingredient (API) primary particle size within the un-compacted fraction was also shown to have undergone notable size reduction. The aim of the current work was to test the hypothesis that the observations may be more indicative of the relative compactability of the API due to the formulation being above the percolation threshold.

This was done by assessing the impact of varied API loads in the formulation on the non-granulated fraction of the final granulate and the extent of attrition of API particles within the non-granulated fraction. The influence of processing conditions for all formulations was also investigated. The results verify that the observations, both of this study and the previous work, are not a consequence of exceeding the percolation threshold. The volume of un-compacted material within the granulate samples was observed to range between 34.7 and 65.5% depending on the API load and roll pressure, whilst the API attrition was equivalent across all conditions.

Read more here

Clarke, J., Gamble, J.F., Jones, J.W. et al. Determining the Impact of Roller Compaction Processing Conditions on Granulate and API Properties: Impact of Formulation API Load. AAPS PharmSciTech 25, 24 (2024). https://doi.org/10.1208/s12249-024-02744-7

Read more on Roller Compaction here:

• Challenges encountered in the transfer of atorvastatin tablet manufacturing
• From Screening to Downstreaming
• Combined DEM and Johanson model for ribbon density prediction in a roller compactor